SCHEMBL6154816

SCHEMBL6154816

Cc1ccnn1CC(C)C

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.47
ALDH1A1 P00352 4/20 0.40
LMNA P02545 4/20 0.37
TDP1 Q9NUW8 1/20 0.37
CBLB Q13191 1/20 0.36
GRM2 Q14416 1/20 0.35
KDM4E B2RXH2 3/20 0.34
HPGD P15428 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C19 P33261 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
APOBEC3G Q9HC16 2/20 0.33
GAA P10253 1/20 0.33
ELOVL1 Q9BW60 2/20 0.33
PIK3CD O00329 1/20 0.33
TSHR P16473 1/20 0.33
HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31030362 0.83 MAPK1 (0.49) MAPK1ALDH1A1LMNACBLBKDM4E
SCHEMBL12512974 0.83 MAPK1 (0.44) MAPK1ALDH1A1LMNATDP1CBLB
SCHEMBL12434717 0.83 MAPK1 (0.44) MAPK1ALDH1A1LMNATDP1CBLB
SCHEMBL8141395 0.83 MAPK1 (0.44) MAPK1ALDH1A1LMNACBLBCYP1A2
SCHEMBL18806993 0.83 MAPK1 (0.49) MAPK1ALDH1A1LMNACBLBKDM4E
SCHEMBL21587664 0.81 MAPK1 (0.46) MAPK1ALDH1A1LMNACBLBCYP1A2
SCHEMBL16548434 0.79 MAPK1 (0.53) MAPK1ALDH1A1CYP1A2CYP2C19ELOVL1
SCHEMBL23138107 0.77 S1PR1 (0.34) MAPK1ALDH1A1LMNATDP1GRM2
SCHEMBL20197167 0.77 GRM2 (0.34) MAPK1LMNAGRM2PIK3CD
SCHEMBL22633135 0.77 KDM4E (0.48) MAPK1ALDH1A1LMNATDP1GRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024059665-A1 DIMERIC COMPOUNDS AS INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF MAZE THERAPEUTICS, INC. (US) 2024-03-21 WO disclosed
WO-2023192901-A9 QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS ESCIENT PHARMACEUTICALS, INC. (US) 2023-12-14 WO disclosed
US-11814367-B2 Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof MAZE THERAPEUTICS, INC. (US) 2023-11-14 US disclosed
US-11814367-B2 Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof MAZE THERAPEUTICS, INC. (US) 2023-11-14 US disclosed
WO-2023192901-A1 QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS ESCIENT PHARMACEUTICALS, INC. (US) 2023-10-05 WO disclosed
US-11771738-B2 Endoparasitic depsipeptides ZOETIS SERVICES LLC (US) 2023-10-03 US disclosed
WO-2022198196-A1 INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF MAZE THERAPEUTICS, INC. (US) 2022-09-22 WO disclosed
US-11377425-B1 Small molecule modulators of IL-17 LEO PHARMA A/S (DK) 2022-07-05 US disclosed
WO-2020200154-A1 A CLASS OF THIOPHENE FUSED N-HETEROCYCLIES, PREPARATION METHOD AND USE 上海凌达生物医药有限公司 2020-10-08 WO disclosed
WO-2020127685-A1 AMINO-ACID ANILIDES AS SMALL MOLECULE MODULATORS OF IL-17 LEO PHARMA A/S (DK) 2020-06-25 WO disclosed
US-9670172-B2 Heterocyclic compounds and methods of use MEDIVATION TECHNOLOGIES, INC. (US) 2017-06-06 US disclosed
US-20160237072-A1 OXAZOLIDINONES AS MODULATORS OF MGLUR5 BRISTOL MYERS SQUIBB CO (US) 2016-08-18 US disclosed
US-20150065519-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE MEDIVATION TECHNOLOGIES LLC 2015-03-05 US disclosed
US-20110178092-A1 HIV-1 Protease Inhibitors UNIVERSITY OF MARYLAND, COLLEGE PARK 2011-07-21 US disclosed
CN-101066950-A 4-amino-5-methylpyrazole derivatives and process for producing the same SANKYO AGRO CO LTD (JP) 2007-11-07 CN disclosed
CN-101062918-A 4-amino-5-methylpyrazole derivatives and process for producing the same SANKYO AGRO CO LTD (JP) 2007-10-31 CN disclosed
CN-101062917-A 4-amino-5-methylpyrazole derivatives and process for producing the same SANKYO AGRO CO LTD (JP) 2007-10-31 CN disclosed
CN-1732155-A 4-amino-5-methylpyrazole derivatives and process for producing the same SANKYO AGRO CO LTD (JP) 2006-02-08 CN disclosed
EP-1580189-A1 4-AMINO-5-METHYLPYRAZOLE DERIVATIVES AND PROCESS FOR PRODUCTION THEREOF Sankyo Agro Company, Limited (JP) 2005-09-28 EP disclosed
EP-1329160-A2 4-ACYLAMINOPYRAZOLE DERIVATIVES Sankyo Company, Limited (JP) 2003-07-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11814367-B2 Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof GYS2, GYS1, PYGL MAPK1 652/4885ALDH1A1 2458/4885LMNA 393/4885
US-20110178092-A1 HIV-1 Protease Inhibitors SERPINB1, PRSS1, TMPRSS4 MAPK1 3160/4885ALDH1A1 2716/4885LMNA 2776/4885
US-11377425-B1 Small molecule modulators of IL-17 IL17A, IL15, IL2 MAPK1 1391/4885ALDH1A1 401/4885LMNA 3720/4885
US-20150065519-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE HRAS, VHL, ESRRB MAPK1 2209/4885ALDH1A1 2384/4885LMNA 2671/4885
US-11771738-B2 Endoparasitic depsipeptides VIP, PREP, VIPR1 MAPK1 2900/4885ALDH1A1 2109/4885LMNA 2449/4885
US-20160237072-A1 OXAZOLIDINONES AS MODULATORS OF MGLUR5 GRM5, GRIK5, GRM1 MAPK1 1328/4885ALDH1A1 3633/4885LMNA 4607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.